Evidence map›Paper›PMID 39483149›Full record

ArticleInternational journal of cardiology. Heart & vasculature2024

The myocardial function index (MFI): An integrated measure of cardiac function in AL-cardiomyopathy.

Nadia Akhiyat, Vidhu Anand, Vinayak Kumar, Alexander Ryu, Raymond Gibbons, Barry A Borlaug, Krishnaswamy Chandrasekaran, Omar Abou Ezzeddine, Nandan Anavekar

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nadia AkhiyatDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Vidhu AnandDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Vinayak KumarDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Alexander RyuDivision of Hospital Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Raymond GibbonsDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Barry A BorlaugDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Krishnaswamy ChandrasekaranDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Omar Abou EzzeddineDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Nandan AnavekarDivision of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Amyloid light chain (AL) amyloidosis is a systemic disease that can cause restrictive cardiomyopathy (AL-CM). Current imaging techniques are not sensitive to detect myocardial dysfunction in AL-CM. We sought to evaluate role of a novel marker of myocardial dysfunction (myocardial function index, MFI) obtained using changes in left ventricular (LV) blood pool and myocardial volume in diastole and systole. Methods: Consecutive patients diagnosed with AL-CM who had underwent cardiac MRI between 2001-2017 were identified and compared to healthy individuals. Two independent operators used cardiac MRI to perform epicardial and endocardial tracings in systole and diastole to obtain myocardial volume in diastole (MVd) and myocardial volume in systole (MVs). Changes in myocardial volumes during the cardiac cycle were measured to calculate the MFI by Results: Patients with AL-CM (n = 129, 61 ± 10 years, 32 % women) were older and more likely to be men compared to the normal cohort (n = 101, 39 ± 15 years, 61 % women). MFI was lower in patients with AL-CM (19 % [15; 23] vs 38 % [35; 41], p < 0.001) and MFI < 30 % discriminated between AL-CM with 92 % sensitivity and 100 % specificity (AUC 0.98, p < 0.001). Higher MFI was independently associated with survival even after adjusting for conventional prognostic biomarkers of AL-CM (HR 0.02, 95 % CI 2.23 *104 - 0.24, p < 0.05). Two independent operators demonstrated high intra and inter-rater correlation in measurements used to calculate MFI. Conclusion: MFI is a novel metric for assessing LV function. It is abnormal in patients with AL-CM and may play a role in risk stratification.

Indexed as

Cardiac amyloidosisCardiac MRIRisk marker

Identifiers

PMID39483149
PMCPMC11525457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.